ID   MDA231-BrM2-831
AC   CVCL_VR36
SY   MDA 231 BrM2 831; MDA-MB-231-BrM2 831; MDA231-BrM2
DR   GEO; GSM2194109
DR   GEO; GSM2194110
DR   GEO; GSM2194111
RX   PubMed=19421193;
RX   PubMed=28283064;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Characteristics: Established from MDA231-TGL cell line after 2 passage in nude mice.
CC   Sequence variation: Heterozygous for BRAF p.Gly464Val (c.1391G>T) (from parent cell line).
CC   Sequence variation: Homozygous for CDKN2A deletion (from parent cell line).
CC   Sequence variation: Heterozygous for KRAS p.Gly13Asp (c.38G>A) (from parent cell line).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Arg280Lys (c.839G>A) (from parent cell line).
CC   Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK.
CC   Omics: Deep RNAseq analysis.
CC   Miscellaneous: STR profile from MSKCC antibody and bioresource core facility.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): MSKCC
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D10S1248: 14,16
ST   D12S391: 17
ST   D13S317: 13
ST   D16S539: 12
ST   D18S51: 11,16
ST   D19S433: 11
ST   D1S1656: 15,17
ST   D21S11: 33.2
ST   D22S1045: 16
ST   D2S1338: 20,21
ST   D2S441: 14,15
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8
ST   D8S1179: 13
ST   FGA: 22,23
ST   Penta D: 14
ST   Penta E: 11
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_VR35 ! MDA231-TGL
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 06-09-19; Version: 4
//
RX   PubMed=19421193; DOI=10.1038/nature08021;
RA   Bos P.D., Zhang X.H.-F., Nadal C., Shu W., Gomis R.R., Nguyen D.X.,
RA   Minn A.J., van de Vijver M.J., Gerald W.L., Foekens J.A.,
RA   Massague J.;
RT   "Genes that mediate breast cancer metastasis to the brain.";
RL   Nature 459:1005-1009(2009).
//
RX   PubMed=28283064; DOI=10.1016/j.cell.2017.02.025;
RA   Boire A., Zou Y., Shieh J., Macalinao D.G., Pentsova E., Massague J.;
RT   "Complement component 3 adapts the cerebrospinal fluid for
RT   leptomeningeal metastasis.";
RL   Cell 168:1101-1113.e13(2017).
//